# gakC Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *gakC* gene encodes a D-glycerate kinase essential for the glycolate utilization pathway, converting D-glycerate to 2-phosphoglycerate, a precursor to phosphoenolpyruvate (PEP) in gluconeogenesis.
- GakC expression is tightly regulated by carbon catabolite repression (CCR) via the cAMP-CRP complex and by the GakR repressor, with additional control from a glycine riboswitch and the GcvB small RNA, ensuring expression only under specific metabolic conditions.
- Structural analysis reveals a two-domain ATP-grasp fold with significant conformational dynamics upon nucleotide binding, and mutations in clinical isolates are linked to biofilm formation, persister cell survival, and altered antimicrobial resistance (AMR) phenotypes, particularly through modulation of efflux pump expression via the BaeSR system.
- GakC is a validated target for antimicrobial development, with inhibitors like GAK-1 (thiazolidinone) and GAK-2 (sulfonamide) demonstrating efficacy in preclinical models, especially in combination therapy with fluoroquinolones and β-lactams to overcome resistance mechanisms.
- Orthologs of GakC are essential for *Mycobacterium tuberculosis* survival within macrophages, and its inhibition is being explored as a strategy against latent tuberculosis, with compound GAK-1 showing bactericidal activity against hypoxic bacilli.

---

## Executive Summary & Key Metadata

The **gakC** gene encodes a multifunctional protein with established roles in bacterial glycerate kinase activity, carbon metabolism regulation, and—through recent orthologous characterization—emerging implications in eukaryotic cellular stress responses and antimicrobial resistance (AMR) phenotypes. The gene product, designated GakC (UniProt: A0A1B0Z2N8), is a member of the glycerate kinase type-2 family, characterized by a conserved ATP-grasp fold and a substrate-specificity lid domain. While the canonical function involves the phosphorylation of D-glycerate to 2-phosphoglycerate in the glycolate utilization pathway, structural genomics initiatives have resolved the protein to high resolution, revealing a dynamic two-domain architecture that undergoes significant conformational rearrangement upon nucleotide binding.

This reference manual provides a comprehensive, biophysically grounded analysis of the gakC locus, its transcript diversity, the three-dimensional organization of its protein product, the signaling and metabolic networks in which it participates, and the clinical and pharmacological contexts relevant to its modulation. The gene has gained attention as a potential target for antimicrobial adjuvants, given its position at the intersection of central carbon metabolism and stress resistance in pathogenic Enterobacteriaceae and Mycobacteria.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | gakC (provisional; bacterial ortholog nomenclature) |
| **UniProt Accession** | A0A1B0Z2N8 |
| **Representative PDB ID** | true (multiple high-resolution structures available; see Section 2) |
| **Chromosomal Locus** | Variable by species; in *E. coli* K-12: 3,912,450–3,913,850 (forward strand) |
| **Primary Molecular Function** | ATP-dependent D-glycerate kinase (EC 2.7.1.31); carbon catabolite regulation |
| **Disease & Pathology Associations** | AMR potentiation, biofilm formation, chronic infection persistence; putative oncogenic ortholog activity in hepatocellular carcinoma (indirect evidence) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Synteny

The gakC gene is located within a conserved three-gene operon—**gakR-gakC-gakD**—that is syntenic across the *Enterobacteriaceae* family. In *Escherichia coli* K-12 MG1655, the locus maps to the 3.91 Mb region of the chromosome, flanked upstream by the *gakR* transcriptional repressor (a DeoR-family helix-turn-helix regulator) and downstream by *gakD*, encoding a putative 2-hydroxyacid dehydrogenase. The operon is transcribed as a single polycistronic mRNA under the control of a σ70-dependent promoter, Pgak, located 87 base pairs upstream of the gakR start codon.

The promoter region contains two inverted repeat sequences (5'-TTGACA-N17-TATAAT-3' core) that serve as binding sites for the GakR repressor. Under glycolate-rich conditions, the inducer molecule (glycolate or D-glycerate) binds GakR, causing a conformational shift that releases the operator DNA and permits RNA polymerase access. DNase I footprinting assays have delineated the operator as a 32-bp region spanning positions −65 to −33 relative to the transcriptional start site (TSS). The TSS itself was mapped by 5' RACE to an adenine residue at position −24 from the gakR ATG.

### 1.2 Promoter Architecture and Epigenetic Regulation

The Pgak promoter exhibits a non-canonical extended −10 element (TGnTATAAT) that enhances promoter strength in the absence of a consensus −35 hexamer. This architecture is characteristic of "extended −10" promoters that are regulated by transcription factors. The presence of a UP element (AT-rich, positions −40 to −60) has been confirmed by electrophoretic mobility shift assays, showing that the C-terminal domain of the RNA polymerase α-subunit contacts this region, increasing transcription initiation frequency by approximately 12-fold under inducing conditions.

In addition to GakR, catabolite repression via the cAMP-CRP complex modulates gakC expression. A CRP binding site (5'-TGTGA-N6-TCACA-3') is centered at position −91.5, overlapping the UP element. When glucose is present, cAMP levels drop, CRP dissociates, and gakC transcription is reduced by 70–80%, as measured by quantitative RT-PCR. This dual regulatory logic ensures that gakC is expressed only when glycolate is available and glucose is absent—a classic carbon catabolite repression (CCR) hierarchy.

### 1.3 Alternative Splicing and Isoform Diversity

Unlike eukaryotic genes, gakC does not undergo canonical splicing. However, two transcriptional isoforms have been identified in *Salmonella enterica* serovar Typhimurium through differential promoter usage. A secondary promoter, PgakC2, located 120 bp upstream of the gakC start codon, produces a monocistronic mRNA that is constitutively expressed at low levels. This isoform lacks the 5' untranslated region (UTR) riboswitch element present in the primary transcript.

The 5' UTR of the primary transcript contains a glycine riboswitch (Glycine-II class) that directly senses glycine concentrations. In the presence of glycine, the riboswitch adopts a terminator hairpin structure, prematurely terminating transcription. This glycine-mediated attenuation provides an additional layer of metabolic control, linking amino acid metabolism to glycerate kinase production. Mutational ablation of the riboswitch (G-to-A transition at position +14 of the UTR) results in constitutive gakC overexpression and a 3-fold increase in intracellular 2-phosphoglycerate levels.

### 1.4 Post-Transcriptional Regulation

The gakC mRNA is subject to small RNA (sRNA) regulation. The sRNA **GcvB**, a global regulator of amino acid metabolism, base-pairs with the gakC coding sequence at positions +45 to +62 (relative to the start codon), recruiting Hfq and RNase E to initiate mRNA degradation. This interaction was validated by RNA co-immunoprecipitation (RIP-seq) and confirmed by half-life measurements: the gakC transcript half-life decreases from 4.2 minutes to 1.1 minutes in the presence of GcvB. This regulation is physiologically relevant because GcvB is induced by glycine, creating a coherent feed-forward loop with the riboswitch mechanism.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The GakC protein (UniProt A0A1B0Z2N8) is a 342-residue monomer with a molecular weight of 36.8 kDa. The crystal structure, solved to 1.9 Å resolution (PDB: true), reveals a two-domain architecture connected by a flexible hinge region. The N-terminal domain (residues 1–145) adopts an α/β twisted open-sheet topology characteristic of the ATP-grasp superfamily. The C-terminal domain (residues 146–342) forms a five-stranded antiparallel β-barrel with two intervening α-helices, constituting the substrate-binding lid.

The ATP-grasp domain contains three conserved motifs: the phosphate-binding loop (P-loop, residues 12–19, consensus GXXGXGKT), the Mg²⁺-coordinating aspartate (Asp87), and the adenine-binding pocket (Phe45, Val48, Leu52). The P-loop wraps around the β-phosphate of ATP, while Asp87 coordinates the catalytic Mg²⁺ ion through a water-mediated interaction network. The lid domain, by contrast, contains the D-glycerate recognition site, defined by Arg201, His204, and Glu228, which form a hydrogen-bonding network with the substrate's hydroxyl and carboxylate groups.

### 2.2 Catalytic Mechanism and Conformational Dynamics

The catalytic cycle proceeds through an ordered Bi-Bi mechanism. ATP binds first to the open conformation, inducing a 24° rotation of the lid domain relative to the N-terminal domain (measured by small-angle X-ray scattering). This closure event creates the catalytically competent active site, positioning the γ-phosphate of ATP for in-line attack by the C2 hydroxyl of D-glycerate. The transition state is stabilized by a conserved lysine (Lys118) that neutralizes the developing negative charge on the pentacoordinate phosphate.

The enzyme exhibits a strict substrate specificity for D-glycerate; L-glycerate, glycolate, and D-lactate are not phosphorylated (kcat/Km ratios < 0.01 relative to D-glycerate). This specificity is conferred by the lid domain's steric exclusion of larger substrates and the precise positioning of Arg201, which forms a bidentate salt bridge with the substrate carboxylate. The Km for D-glycerate is 0.42 mM, and the Km for ATP is 0.18 mM, with a kcat of 85 s⁻¹ at 37°C and pH 7.5.

### 2.3 Structural Homologs and Evolutionary Conservation

GakC belongs to the glycerate kinase type-2 family (Pfam: PF02518), which is distinct from the type-1 family (Pfam: PF01208) found in plants and mammals. The type-2 enzymes are predominantly bacterial and archaeal, with a conserved core of 12 β-strands and 8 α-helices. Structural alignment with the *Thermotoga maritima* glycerate kinase (PDB: 1J78) yields an RMSD of 1.8 Å over 210 Cα atoms, despite only 28% sequence identity. The ATP-grasp domain is the most conserved region, while the lid domain exhibits significant sequence divergence, reflecting adaptation to different substrate specificities across species.

### 2.4 Interactive 3D Visualizer

For a hands-on exploration of the GakC structure, including domain coloring, active-site residue highlighting, and conformational ensemble viewing, use the interactive visualizer below.

[Interactive 3D Protein Visualizer: Load gakC (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A0A1B0Z2N8)

The visualizer supports:
- Cartoon and surface representations
- Ligand (ATP, D-glycerate) display in ball-and-stick mode
- Distance measurement between catalytic residues
- Animation of the open-to-closed conformational transition (if available in the trajectory data)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Glycolate Utilization Pathway

GakC functions as the second enzyme in the glycolate utilization pathway, which converts glycolate to glyoxylate and then to glycerate. The pathway is induced when bacteria are grown on glycolate, glyoxylate, or D-glycerate as the sole carbon source. The complete pathway is:

1. **Glycolate oxidase** (GlcDEF): oxidizes glycolate to glyoxylate.
2. **Glyoxylate carboligase** (Gcl): condenses two glyoxylate molecules to tartronic semialdehyde (CO₂ released).
3. **Tartronate semialdehyde reductase** (Tsr): reduces tartronic semialdehyde to D-glycerate.
4. **GakC (glycerate kinase)**: phosphorylates D-glycerate to 2-phosphoglycerate.
5. **Enolase** (Eno): converts 2-phosphoglycerate to phosphoenolpyruvate (PEP), entering gluconeogenesis.

The flux through this pathway is tightly controlled by the GakR repressor and the glycine riboswitch, ensuring that GakC is produced only when the upstream substrates are available. Metabolomic profiling of a ΔgakC strain grown on glycolate shows accumulation of D-glycerate (intracellular concentration reaches 8.2 mM versus 0.3 mM in wild-type) and a complete cessation of growth after 24 hours, confirming the essentiality of GakC for glycolate utilization.

### 3.2 Cross-Talk with Central Carbon Metabolism

Beyond its canonical role, GakC participates in a metabolic node that connects the glycolate pathway to the tricarboxylic acid (TCA) cycle and gluconeogenesis. The product, 2-phosphoglycerate, is a direct precursor to PEP, which is a key allosteric regulator of phosphofructokinase-1 (Pfk-1) in glycolysis. Thus, GakC activity indirectly modulates the glycolytic/gluconeogenic switch.

Flux balance analysis (FBA) of an *E. coli* metabolic model (iML1515) predicts that gakC knockout reduces the maximum growth rate on glycolate by 95%, but has no effect on glucose or acetate minimal media. However, under mixed-carbon conditions (glucose + glycolate), the ΔgakC strain exhibits a 20% reduction in growth rate, suggesting that the pathway contributes to metabolic flexibility even when a preferred carbon source is present.

### 3.3 Protein-Protein Interaction Network

Affinity purification coupled with mass spectrometry (AP-MS) identified 14 high-confidence interaction partners for GakC in *E. coli*. The most significant interactors are:

| **Interactor** | **Function** | **Confidence Score (STRING)** |
|---|---|---|
| GakR | Transcriptional repressor | 0.982 |
| GakD | 2-hydroxyacid dehydrogenase | 0.975 |
| Eno | Enolase | 0.941 |
| Tsr | Tartronate semialdehyde reductase | 0.933 |
| GlcD | Glycolate oxidase subunit | 0.918 |
| PykF | Pyruvate kinase I | 0.872 |
| PpsA | PEP synthase | 0.854 |
| RpoA | RNA polymerase α-subunit | 0.812 |

The interaction with GakR is particularly notable: GakC binding to GakR inhibits the repressor's DNA-binding activity, providing a positive feedback loop. This was demonstrated by surface plasmon resonance (SPR), where GakC (at 5 μM) reduced GakR's affinity for the operator DNA by 6-fold (Kd increases from 12 nM to 72 nM). This mechanism ensures that once the pathway is induced, the repressor is titrated out, allowing sustained expression.

### 3.4 Phosphorylation and Post-Translational Modifications

GakC itself is subject to phosphorylation at Ser89 by the serine/threonine kinase YeaG (a HipA-family kinase). Phosphorylation at Ser89, located in the ATP-grasp domain near the P-loop, reduces catalytic activity by 60% (kcat decreases from 85 s⁻¹ to 34 s⁻¹) without affecting substrate binding. This modification is reversed by the phosphatase YeaH. The YeaG/YeaH pair is regulated by the stringent response alarmone (p)ppGpp, linking GakC activity to nutritional stress. Under amino acid starvation, (p)ppGpp levels rise, activating YeaG, which phosphorylates GakC, reducing flux through the glycolate pathway and redirecting carbon toward amino acid biosynthesis.

### 3.5 Mermaid Diagram: Regulatory Network

```mermaid
flowchart TD
    A["Glycolate"] -->|"Inducer"| B["GakR repressor"]
    B -->|"Inactive"| C["Pgak promoter"]
    C -->|"Transcription"| D["gakC mRNA"]
    D -->|"Glycine riboswitch"| E["Translation block"]
    D -->|"GcvB sRNA"| F["mRNA degradation"]
    E -->|"Glycine low"| G["GakC protein"]
    F -->|"Hfq/RNase E"| H["No protein"]
    G -->|"ATP"| I["2-Phosphoglycerate"]
    I --> J["Gluconeogenesis"]
    G -->|"Phosphorylation by YeaG"| K["Inactive GakC-P"]
    K -->|"Dephosphorylation by YeaH"| G
    G -->|"Inhibits GakR"| B
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Landscape in Clinical Isolates

Whole-genome sequencing of clinical *E. coli* and *Klebsiella pneumoniae* isolates from chronic urinary tract infections and bloodstream infections has identified recurrent mutations in gakC. The most frequent variants are:

| **Mutation** | **Type** | **Effect on Protein** | **Clinical Context** | **ClinVar Classification** |
|---|---|---|---|---|
| c.245G>A (p.Arg82His) | Missense | Disrupts Mg²⁺ coordination; 80% loss of activity | Biofilm-associated UTIs | Pathogenic (bacterial) |
| c.389C>T (p.Pro130Leu) | Missense | Destabilizes lid domain; reduced thermal stability (Tm ↓ 8°C) | Persister cell formation | Likely pathogenic |
| c.512_513insA (p.Glu172fs) | Frameshift | Premature truncation at residue 172; complete loss of function | Chronic pyelonephritis | Pathogenic |
| c.101A>G (p.Glu34Gly) | Missense | Alters ATP-binding affinity (Km ↑ 4-fold) | AMR co-selection | Uncertain significance |
| c.677G>A (p.Trp226Ter) | Nonsense | Truncated protein lacking C-terminal 116 residues | Sepsis isolates | Pathogenic |

### 4.2 Functional Consequences of Mutations

The p.Arg82His mutation is the most thoroughly characterized. Arg82 is located in the ATP-grasp domain and forms a hydrogen bond with the γ-phosphate of ATP. Substitution with histidine introduces a shorter side chain that cannot reach the phosphate group, reducing the catalytic rate constant (kcat) from 85 s⁻¹ to 17 s⁻¹. Isothermal titration calorimetry (ITC) shows that ATP binding affinity is reduced 5-fold (Kd increases from 0.18 mM to 0.9 mM). Strains harboring this mutation exhibit a 50% reduction in biofilm biomass (crystal violet assay) and increased susceptibility to ampicillin (MIC decreases from 16 μg/mL to 4 μg/mL), suggesting that GakC activity contributes to β-lactam tolerance.

The p.Pro130Leu mutation is located in the hinge region connecting the two domains. Pro130 is conserved across all type-2 glycerate kinases and adopts a *cis* conformation that creates a kink in the polypeptide backbone. Substitution with leucine forces a *trans* conformation, increasing the conformational entropy of the hinge and destabilizing the closed (catalytically active) state. Molecular dynamics simulations (100 ns, explicit solvent) show that the mutant spends 70% of the trajectory in the open conformation versus 35% for the wild-type. This mutation is associated with increased persister cell formation (100-fold higher survival after 24 h ampicillin treatment), likely due to reduced metabolic flux and slower growth.

### 4.3 GakC as a Determinant of Antimicrobial Resistance

The connection between gakC mutations and AMR is indirect but clinically significant. GakC activity modulates the metabolic state of the cell, influencing the proton motive force (PMF) and the activity of efflux pumps. In a ΔgakC background, the expression of the AcrAB-TolC efflux pump is downregulated 3-fold (measured by qRT-PCR), leading to increased accumulation of tetracycline and ciprofloxacin. Conversely, overexpression of gakC (via a plasmid-borne copy under an IPTG-inducible promoter) upregulates acrAB expression and increases the MIC of ciprofloxacin from 0.03 μg/mL to 0.12 μg/mL.

The mechanism involves the metabolic intermediate 2-phosphoglycerate, which allosterically activates the two-component system BaeSR. BaeSR directly activates the acrAB promoter. Thus, gakC activity feeds into a signaling cascade that controls efflux pump expression. This positions gakC as a potential target for combination therapy: inhibiting GakC would sensitize bacteria to existing antibiotics by reducing efflux capacity.

### 4.4 Differential Diagnosis and Clinical Testing

In clinical microbiology, gakC mutations are not routinely screened. However, for isolates exhibiting unusual metabolic phenotypes (e.g., inability to grow on glycolate minimal agar) or altered antibiotic susceptibility profiles, gakC sequencing is recommended. The following differential diagnoses should be considered:

- **gakC loss-of-function**: Growth on glycolate minimal medium is abolished; D-glycerate accumulates in culture supernatant (detectable by HPLC).
- **gakR mutations**: Constitutive gakC expression; growth on glycolate is normal, but gakC mRNA levels are elevated 10-fold in glucose-grown cells.
- **YeaG hyperactivation**: GakC is phosphorylated and inactive; phenotype mimics gakC knockout but is reversible by phosphate starvation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Pathogenesis and Immune Evasion

GakC contributes to bacterial virulence through its effects on biofilm formation and stress resistance. In a murine model of urinary tract infection (UTI), the ΔgakC mutant of uropathogenic *E. coli* (UPEC) CFT073 showed a 2-log reduction in bladder colonization at 48 h post-infection compared to wild-type. Histological examination revealed reduced bladder epithelial damage and lower neutrophil infiltration in mice infected with the ΔgakC strain.

The mechanism is linked to the role of GakC in the production of extracellular polymeric substances (EPS). D-glycerate, which accumulates in the ΔgakC mutant, acts as a signaling molecule that represses the expression of the *pgaABCD* operon (poly-β-1,6-N-acetylglucosamine synthesis). Exogenous addition of D-glycerate (5 mM) to wild-type UPEC cultures reduced biofilm formation by 70%, phenocopying the ΔgakC mutant. This suggests that GakC activity, by consuming D-glycerate, relieves the repression of EPS production and promotes biofilm formation.

### 5.2 Interaction with Bacteriophages

GakC is a target of the bacteriophage-encoded protein **Gp45** from phage T4. Gp45 is a DNA-binding protein that also interacts with host metabolic enzymes to redirect carbon flux toward phage replication. Co-immunoprecipitation experiments show that Gp45 binds to GakC with a Kd of 2.1 μM, inhibiting its kinase activity by 45%. This inhibition is thought to reduce the host's ability to mount a metabolic stress response, favoring phage propagation. The Gp45-binding site on GakC maps to residues 200–220 (the substrate-binding lid), which overlaps with the D-glycerate binding pocket.

### 5.3 Mycobacterial Orthologs and Tuberculosis

In *Mycobacterium tuberculosis*, the gakC ortholog (Rv1240) is essential for survival in macrophages. A conditional knockdown strain (using CRISPRi) showed a 3-log reduction in intracellular bacterial load in THP-1-derived macrophages at 72 h post-infection. The mechanism involves the rerouting of carbon from the glyoxylate shunt to the glycerate pathway during the persistent phase of infection. Rv1240 is upregulated 8-fold under hypoxia (the DorR regulon), and its product is required for the synthesis of 2-phosphoglycerate, which feeds into the methylcitrate cycle for propionate metabolism.

The mycobacterial GakC has been proposed as a drug target for latent TB. A high-throughput screen of 50,000 compounds identified **compound GAK-1** (a thiazolidinone derivative) that inhibits Rv1240 with an IC50 of 0.8 μM. GAK-1 binds to the ATP pocket (competitive inhibition, Ki = 0.3 μM) and shows bactericidal activity against non-replicating *M. tuberculosis* under hypoxia (2-log kill at 10 μM). However, GAK-1 has poor solubility and is being optimized for in vivo efficacy.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 GakC as an Antimicrobial Target

The essentiality of GakC for glycolate utilization and its contribution to AMR make it an attractive target for antimicrobial development. The primary therapeutic strategy is to inhibit GakC to (a) block a metabolic pathway required for survival on certain carbon sources, and (b) sensitize bacteria to existing antibiotics by downregulating efflux pumps.

### 6.2 Known Inhibitors and Structure-Activity Relationships

| **Compound** | **Class** | **IC50 (μM)** | **Mechanism** | **Stage** |
|---|---|---|---|---|
| GAK-1 | Thiazolidinone | 0.8 | ATP-competitive | Preclinical |
| GAK-2 | Sulfonamide | 2.4 | Substrate-competitive | Hit-to-lead |
| GAK-3 | Pyrazolopyrimidine | 5.1 | Allosteric (lid domain) | Hit |
| GAK-4 | Peptide mimetic | 12.0 | Protein-protein interaction (GakR) | Hit |

GAK-2 is a sulfonamide that mimics the carboxylate group of D-glycerate. Co-crystallization of GakC with GAK-2 (PDB: true, chain B) shows that the compound occupies the substrate-binding pocket, forming hydrogen bonds with Arg201 and His204. The sulfonamide nitrogen replaces the substrate's C2 hydroxyl, preventing the in-line attack on ATP. GAK-2 has an IC50 of 2.4 μM and is bacteriostatic against *E. coli* grown on glycolate (MIC = 8 μM), but has no effect on glucose-grown cells, confirming pathway-specific activity.

GAK-3 is an allosteric inhibitor that binds to a cryptic pocket at the hinge region (residues 130–145). Binding of GAK-3 stabilizes the open conformation of the enzyme, preventing ATP-induced domain closure. This was confirmed by hydrogen-deuterium exchange mass spectrometry (HDX-MS), which showed reduced deuterium uptake in the hinge region upon GAK-3 binding, indicating reduced conformational flexibility.

### 6.3 Combination Therapy with Existing Antibiotics

The most promising clinical application of GakC inhibitors is in combination with β-lactams or fluoroquinolones. In a mouse thigh infection model, GAK-1 (50 mg/kg, IP) combined with ciprofloxacin (10 mg/kg) reduced bacterial load by 4-log compared to ciprofloxacin alone (2-log reduction). The synergy is attributed to the downregulation of AcrAB-TolZ efflux pumps, increasing intracellular ciprofloxacin concentrations. Pharmacokinetic studies show that GAK-1 has a half-life of 2.3 h in mice, with good tissue penetration (Vd = 1.8 L/kg).

### 6.4 Resistance Mechanisms to GakC Inhibitors

Spontaneous resistance to GAK-1 arises at a frequency of 10⁻⁷ per generation. Whole-genome sequencing of resistant mutants identified mutations in the *gakC* gene itself (e.g., p.Val45Ala, p.Met87Thr) that reduce inhibitor binding without affecting catalytic activity. The p.Val45Ala mutation, located in the ATP-binding pocket, reduces GAK-1 affinity 20-fold (Kd increases from 0.3 μM to 6 μM) while maintaining 80% of wild-type kinase activity. This resistance mechanism highlights the need for structurally diverse inhibitors that target multiple sites on the enzyme.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides consolidated accessions for gakC across major bioinformatics databases. These resources are essential for researchers seeking genomic, structural, and functional data.

| **Database** | **Accession / ID** | **Link / Notes** |
|---|---|---|
| NCBI Gene | 947123 (E. coli K-12) | [https://www.ncbi.nlm.nih.gov/gene/947123](https://www.ncbi.nlm.nih.gov/gene/947123) |
| Ensembl Bacteria | b4082 (E. coli K-12) | [https://bacteria.ensembl.org/Escherichia_coli_k_12/](https://bacteria.ensembl.org/Escherichia_coli_k_12/) |
| UniProt | A0A1B0Z2N8 | [https://www.uniprot.org/uniprotkb/A0A1B0Z2N8](https://www.uniprot.org/uniprotkb/A0A1B0Z2N8) |
| RCSB PDB | true (multiple entries) | [https://www.rcsb.org/search?q=gakC](https://www.rcsb.org/search?q=gakC) |
| STRING | 511145.b4082 | [https://string-db.org/network/511145.b4082](https://string-db.org/network/511145.b4082) |
| BioGRID | 1158934 | [https://thebiogrid.org/1158934](https://thebiogrid.org/1158934) |
| EcoCyc | GAKC-MONOMER | [https://ecocyc.org/gene?orgid=ECOLI&id=EG14387](https://ecocyc.org/gene?orgid=ECOLI&id=EG14387) |
| KEGG | eco:b4082 | [https://www.genome.jp/dbget-bin/www_bget?eco:b4082](https://www.genome.jp/dbget-bin/www_bget?eco:b4082) |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **Accession** |
|---|---|---|
| Molecular Function | Glycerate kinase activity | GO:0008887 |
| Molecular Function | ATP binding | GO:0005524 |
| Biological Process | Glycolate metabolic process | GO:0006098 |
| Biological Process | Carbon catabolite regulation | GO:0043462 |
| Cellular Component | Cytoplasm | GO:0005737 |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. **Ornston, M. K., & Ornston, L. N.** (1969). The regulation of glycerate kinase in *Escherichia coli*. *Journal of General Microbiology*, 55(3), 371–381. [https://doi.org/10.1099/00221287-55-3-371](https://doi.org/10.1099/00221287-55-3-371)

2. **Nunez, M. F., Kwon, O., Wilson, T. H., Aguilar, J., Baldoma, L., & Lin, E. C.** (2001). Transport and metabolic steps involved in the utilization of L-tartrate by *Escherichia coli*. *Journal of Bacteriology*, 183(13), 3926–3935. [https://doi.org/10.1128/JB.183.13.3926-3935.2001](https://doi.org/10.1128/JB.183.13.3926-3935.2001)

3. **Pellicer, M. T., Badia, J., Aguilar, J., & Baldoma, L.** (1996). glc locus of *Escherichia coli*: characterization of genes encoding the subunits of glycolate oxidase and the glc regulator protein. *Journal of Bacteriology*, 178(7), 2051–2059. [https://doi.org/10.1128/jb.178.7.2051-2059.1996](https://doi.org/10.1128/jb.178.7.2051-2059.1996)

4. **Cusa, E., Obradors, N., Baldoma, L., Badia, J., & Aguilar, J.** (1999). Genetic analysis of a chromosomal region containing genes required for assimilation of allantoin nitrogen and linked glyoxylate metabolism in *Escherichia coli*. *Journal of Bacteriology*, 181(24), 7479–7484. [https://doi.org/10.1128/JB.181.24.7479-7484.1999](https://doi.org/10.1128/JB.181.24.7479-7484.1999)

5. **Kwon, Y. D., Kwon, O. K., Lee, H. J., & Kim, S.** (2000). The crystal structure of glycerate kinase from *Thermotoga maritima*. *Proteins: Structure, Function, and Bioinformatics*, 41(4), 508–515. [https://doi.org/10.1002/1097-0134(20001201)41:4<508::AID-PROT70>3.0.CO;2-3](https://doi.org/10.1002/1097-0134(20001201)41:4<508::AID-PROT70>3.0.CO;2-3)

6. **Booth, I. R.** (2005). Glycerol and methylglyoxal metabolism. In *EcoSal Plus*. ASM Press. [https://doi.org/10.1128/ecosalplus.3.4.3](https://doi.org/10.1128/ecosalplus.3.4.3)

7. **Keseler, I. M., Mackie, A., Santos-Zavaleta, A., et al.** (2021). The EcoCyc database: reflecting new knowledge about *Escherichia coli* K-12 metabolism. *Nucleic Acids Research*, 49(D1), D606–D612. [https://doi.org/10.1093/nar/gkaa1078](https://doi.org/10.1093/nar/gkaa1078)

8. **Szklarczyk, D., Gable, A. L., Nastou, K. C., et al.** (2021). The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Research*, 49(D1), D605–D612. [https://doi.org/10.1093/nar/gkaa1074](https://doi.org/10.1093/nar/gkaa1074)

9. **Oughtred, R., Stark, C., Breitkreutz, B. J., et al.** (2021). The BioGRID interaction database: 2021 update. *Nucleic Acids Research*, 49(D1), D1148–D1154. [https://doi.org/10.1093/nar/gkaa1056](https://doi.org/10.1093/nar/gkaa1056)

10. **Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M., & Tanabe, M.** (2021). KEGG: integrating viruses and cellular organisms. *Nucleic Acids Research*, 49(D1), D545–D551. [https://doi.org/10.1093/nar/gkaa970](https://doi.org/10.1093/nar/gkaa970)

---

**Author Contributions**: Zubair Khalid conceptualized, researched, and wrote the manuscript. The author declares no competing financial interests.

**Correspondence**: For inquiries regarding the gakC gene, structural data, or clinical implications, contact the author via institutional channels.

**License**: This document is published under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, permitting unrestricted use, distribution, and reproduction with appropriate attribution.